Sign In
Buy BKYI
BIO-key International Earnings Calls
| Release date | May 18, 2026 |
| EPS estimate | -$0.600 |
| EPS actual | -$0.150 |
| EPS Surprise | 75.00% |
| Revenue estimate | 2.2M |
| Revenue actual | 2.146M |
| Revenue Surprise | -2.48% |
| Release date | Mar 31, 2026 |
| EPS estimate | -$0.700 |
| EPS actual | -$1.90 |
| EPS Surprise | -171.43% |
| Revenue estimate | 2.2M |
| Revenue actual | 1.241M |
| Revenue Surprise | -43.58% |
| Release date | Nov 14, 2025 |
| EPS estimate | -$0.120 |
| EPS actual | -$0.150 |
| EPS Surprise | -25.00% |
| Revenue estimate | 1.8M |
| Revenue actual | 1.55M |
| Revenue Surprise | -13.91% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.200 |
| EPS Surprise | -33.33% |
| Revenue estimate | 1.7M |
| Revenue actual | 1.697M |
| Revenue Surprise | -0.182% |
Last 4 Quarters for BIO-key International
Below you can see how BKYI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $7.92 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.200 |
| EPS surprise | -33.33% |
| Date | Price |
|---|---|
| Aug 07, 2025 | $7.60 |
| Aug 08, 2025 | $7.53 |
| Aug 11, 2025 | $7.77 |
| Aug 12, 2025 | $8.08 |
| Aug 13, 2025 | $7.92 |
| Aug 14, 2025 | $7.45 |
| Aug 15, 2025 | $7.33 |
| Aug 18, 2025 | $7.80 |
| Aug 19, 2025 | $7.68 |
| 4 days before | 4.22% |
| 4 days after | -3.03% |
| On release day | -5.93% |
| Change in period | 1.07% |
| Release date | Nov 14, 2025 |
| Price on release | $9.47 |
| EPS estimate | -$0.120 |
| EPS actual | -$0.150 |
| EPS surprise | -25.00% |
| Date | Price |
|---|---|
| Nov 10, 2025 | $7.99 |
| Nov 11, 2025 | $8.22 |
| Nov 12, 2025 | $9.35 |
| Nov 13, 2025 | $9.70 |
| Nov 14, 2025 | $9.47 |
| Nov 17, 2025 | $9.74 |
| Nov 18, 2025 | $10.30 |
| Nov 19, 2025 | $9.35 |
| Nov 20, 2025 | $9.20 |
| 4 days before | 18.52% |
| 4 days after | -2.85% |
| On release day | 2.87% |
| Change in period | 15.14% |
| Release date | Mar 31, 2026 |
| Price on release | $5.30 |
| EPS estimate | -$0.700 |
| EPS actual | -$1.90 |
| EPS surprise | -171.43% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $6.14 |
| Mar 26, 2026 | $5.82 |
| Mar 27, 2026 | $5.73 |
| Mar 30, 2026 | $5.98 |
| Mar 31, 2026 | $5.30 |
| Apr 01, 2026 | $5.26 |
| Apr 02, 2026 | $5.43 |
| Apr 06, 2026 | $5.53 |
| Apr 07, 2026 | $5.80 |
| 4 days before | -13.59% |
| 4 days after | 9.41% |
| On release day | -0.85% |
| Change in period | -5.46% |
| Release date | May 18, 2026 |
| Price on release | $4.25 |
| EPS estimate | -$0.600 |
| EPS actual | -$0.150 |
| EPS surprise | 75.00% |
| Date | Price |
|---|---|
| May 12, 2026 | $3.46 |
| May 13, 2026 | $3.46 |
| May 14, 2026 | $3.46 |
| May 15, 2026 | $4.15 |
| May 18, 2026 | $4.25 |
| May 19, 2026 | $4.57 |
| May 20, 2026 | $4.46 |
| May 21, 2026 | $4.65 |
| May 22, 2026 | $4.75 |
| 4 days before | 22.83% |
| 4 days after | 11.76% |
| On release day | 7.53% |
| Change in period | 37.28% |
BIO-key International Earnings Call Transcript Summary of Q1 2026
BIO-key reported strong Q1 2026 results with revenue up 34% year-over-year to $2.1M driven by expanded license renewals (notably a large banking customer) and a >100% increase in hardware sales (including sales of previously fully reserved inventory and defense-related hardware). Gross margin remained high at ~82%. Operating expenses were roughly flat quarter-over-quarter, producing an improved net loss of $165k (versus $737k a year ago). Management reiterated that the business is predominantly subscription-based with a large partner-driven go-to-market (50% domestic new business via partners; 100% international via channel partners). The company highlighted growing traction in defense, financial services and EMEA markets, new partnerships (notably DLT/TD Synnex to reach U.S. public sector customers), and favorable secular trends toward passwordless and biometric authentication. Financial position: book value $7.6M (~$7.04/share), cash ~$2.2M, current assets ~$4.5M. Management expects to file the 2025 Form 10-K imminently, to become current on filings, and is pursuing an appeal hearing (scheduled June 16, 2026) to regain Nasdaq listing; meanwhile shares trade OTC under BKYI. Management expects profitability and positive cash flow in Q2 and is focused on scaling larger, higher-margin deals through partners.
